الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
Egypt has the highest prevalence of hepatitis C virus (HCV) worldwide; it is estimated to be 14.7% among a representative sample of Egyptian population aged 15–59 years. where it bears the highest prevalence rate in the world. Estimates for prevalence are based on data reported from the 2008 and 2015 Egypt Demographic Health Surveys (WHO, 2020) The Ministry of Health introduced the national plan and program for managing HCV, which has been successful so far in treating a large number of patients, with the aim of achieving disease control and eventual elimination of HCV in Egypt (WHO, 2019) Available data with newer all-oral regimens in the treatment of genotype 4 infection suggest that sustained virological response (SVR) 12 rates in treatment-naïve cirrhotic and noncirrhotic patients are greater than 95% (Elnadry et al., 2018) Our study aimed to evaluate patients with chronic HCV related - liver cirrhosis who achieved SVR after DAAs regarding Liver fibrosis (stiffness) using Fibroscan, FIB 4 Score, APPRI Score Liver hemodynamic changes using Doppler Ultrasound. AndClinical status of the patients and liver disease severity using Child and MELD scores. This study was prospective study in which 116 patients with chronic hepatitis C virus related liver cirrhosis who achieved SVR after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin) and other available suitable regimens for 12 or 24 weeks selected from Al-Rajhi Liver Hospital – Assiut University. Laboratory data and imaging assessment were done 3 months after the end of treatment, and 1year after the end of treatment. 100 patients completed the follow up, 16 patients missed follow up (10 patients died & 6 patients lost for follow up).